A5082690204- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Radiopharmaceutical Chemistry and Applications
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Biosimilars and Bioanalytical Methods
- Inflammatory mediators and NSAID effects
- Chronic Lymphocytic Leukemia Research
- Cancer Risks and Factors
- Brain Metastases and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer survivorship and care
- Cancer-related cognitive impairment studies
- Childhood Cancer Survivors' Quality of Life
- Glioma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Bone health and treatments
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Family Support in Illness
University of Arizona
2015-2025
University of Arizona Cancer Center
2015-2025
George Washington University
2023-2024
Wayne State University
2024
Rochester College
2024
Tucson Medical Center
2022
Medizinische Hochschule Hannover
2021
The University of Texas Health Science Center at San Antonio
2017-2020
Mays Cancer Center at UT Health San Antonio
2020
Seattle Cancer Care Alliance
2019
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free (DRFS) hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of prespecified primary outcome analysis an additional analysis.This global, phase III,...
Abstract Purpose: ANG1005, a novel taxane derivative, consists of three paclitaxel molecules covalently linked to Angiopep-2, designed cross the blood–brain and blood–cerebrospinal barriers penetrate malignant cells via LRP1 transport system. Preclinical clinical evidence efficacy with ANG1005 has been previously shown. Patients Methods: A multicenter, open-label phase II study in adult patients measurable recurrent brain metastases from breast cancer (BCBM), or without leptomeningeal...
Objective: The purpose of this study was to test two 2-month psychosocial interventions (Telephone Interpersonal Counseling [TIPC] and Supportive Health Education [SHE]) improve quality life (QOL) outcomes for Latinas with breast cancer their informal caregivers. Methods: Two hundred forty-one caregivers were assessed at baseline, immediately after the intervention, 4 6 months baseline. QOL psychological distress, symptoms social support. Results: Linear mixed effects models showed that...
Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we report results from dose escalation 2 expansion cohorts: Module 1A paired biopsy cohort solid tumor patients, 1B-1 triple negative breast cancer (TNBC) monotherapy expansion, 2A fulvestrant combination HR+/HER2− post-CDK4/6-inhibitor. Core primary...
Abstract PF-06804103 is an anti-HER2 antibody–drug conjugate with auristatin payload. We evaluated its safety, tolerability, and antitumor activity in patients advanced/unresectable or metastatic breast gastric cancers. This multicenter, open-label, first-in-human, phase 1 study (NCT03284723) comprised dose escalation (P1) expansion (P2). In P1, adults HER2+ cancer received 0.15–5.0 mg/kg intravenously once/21 days (Q3W); P2, HER2-low (IHC 1+ IHC 2+/ISH−) 3.0 4.0 Q3W. The primary endpoints...
Abstract Vaccines against SARS-CoV-2 have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. We compared immune responses to the Pfizer/BioNTech mRNA vaccine in solid tumor patients (n=53) on active cytotoxic anti-cancer therapy a control cohort (n=50) as an observational study. Using live assays, neutralizing antibodies detected 67% and 80% of cancer after first second immunizations, respectively, with 3-fold increase median titers...
Objectives: AEG35156 is an antisense oligonucleotide (ASO) that targets the X-linked inhibitor of apoptosis mRNA. Preclinical studies showed potent activity in combination with gemcitabine pancreatic ductal adenocarcinoma (PDA). A phase I study was conducted to establish maximum-tolerated dose, safety, and antitumor plus metastatic PDA. Methods: Fourteen patients PDA were enrolled. Nine treated at 350 mg IV 5 500 AEG35156, 3 weeks on/1 week off a 28-day cycle. Gemcitabine administered 1000...
Abstract Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS). PS externalized on cells in the tumor microenvironment when exposed to hypoxia and/or other physiological stressors. On attaching PS, bavituximab thought promote antitumor immunity through its effects receptors monocytes, and myeloid‐derived suppressor cells, as well trigger by inducing an antibody‐dependent cellular cytotoxicity tumor‐associated endothelial cells. We conducted phase I clinical trial...
Two-thirds of U.S. adult women are overweight or obese. High body mass index (BMI) and weight gain risk factors for a number chronic diseases, including postmenopausal breast cancer. The higher cancer in with elevated BMI is likely to be attributable related metabolic disturbances altered circulating sex steroid hormones adipokines, pro-inflammatory cytokines, insulin resistance. Metformin widely used antidiabetic drug that has demonstrated favorable effects on as such may lead lower obese...
Patients with breast cancer and brain metastases (BM) have a poor prognosis high clinical need for novel treatments; however, historically, studies often excluded these patients. Although the BEACON study did not meet its primary end point, treatment etirinotecan pegol vs chemotherapy of physician's choice patients advanced demonstrated significant improvement in overall survival (OS) prespecified patient subgroup preexisting, pretreated, nonprogressive BM.
Background Little has been reported on suicides among seafarers and how they have changed over time. Aims To establish the causes, rates trends in at work UK merchant shipping from 1919 to 2005 compare suicide with general population employed non-UK shipping. Methods Examination of seafarers' death inquiry files, registers returns (for a total 11.90 million seafarer-years); literature reviews national statistics. Results The rate unexplained disappearances sea) fell 40–50 per 100 000 1920s...
Abstract Introduction BAY 94‐9027 is an extended‒half‐life, site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII). The PROTECT main study demonstrated efficacy of bleed control using extended‐interval prophylaxis with for 36 weeks. Aim To report long‐term and safety in a descriptive analysis the ongoing extension total treatment time up to >5 years. Methods Previously treated males aged 12‐65 years severe haemophilia A who completed were eligible open‐label...
Abstract Introduction: ZN-c3 is a selective and orally bioavailable small molecule WEE1 inhibitor. crucial component of the G2/M cell cycle checkpoint preventing cells from entering mitosis to allow repair DNA damage before progression. has demonstrated significant growth inhibition in vitro multiple lines various cancer types antitumor activity vivo human xenograft tumor models. Methods: ZN-c3-001 (NCT04158336) dose escalation, open-label, multicenter, Phase 1 clinical trial evaluating...
Abstract Purpose: To evaluate the effect of sulindac, a nonselective anti-inflammatory drug (NSAID), for activity to reduce breast density (BD), risk factor cancer. Experimental Design: An open-label phase II study was conducted test 12 months' daily sulindac at 150 mg twice on change in percent BD postmenopausal hormone receptor–positive cancer patients aromatase inhibitor (AI) therapy. Change contralateral, unaffected measured by noncontrast magnetic resonance imaging (MRI) and reported as...